VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AXGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
AXGNAxoGen, Inc.
$44.72$2.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksAXGNCash Flow

AxoGen, Inc. (AXGN) Cash Flow Statement

30Y historyFree accessUpdated daily

Liquidity has improved with a cash position of $82.7M in 2026Q1, yet free cash flow remains erratic, oscillating from a 16.0% margin in 2024Q4 to -2.0% in 2026Q1.

AXGN Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Jun'01Jun'00Jun'99Jun'98Jun'97Jun'96
Cash from Operations15.56M812K4.54M-5.72M-16.07M-13.4M-9.63M-19.87M-17.86M-9.24M-11.2M-13.05M-10.45M-10.44M-8.66M-7.08M-2.43M15.44M-470.16K-466.95K-28.79K-709.62K878.84K-27.3K-755.02K-2.92M-1.27M-200K1.5M100K200K
Operating CF Margin %-0.36%2.42%-3.59%-11.59%-10.53%-8.57%-18.62%-21.28%-15.29%-27.26%-47.75%-62.14%-95.41%-112.61%-145.98%-2661.97%61.99%-646.62%-464.94%-22.73%-160.06%82.52%-0.38%-11.02%-18.35%-8.71%-1.63%11.63%0.81%1.53%
Operating CF Growth %114.87%-82.09%179.34%64.42%-19.85%-39.26%51.56%-11.25%-93.36%17.55%14.15%-24.89%-0.06%-20.58%-22.35%-191.37%-115.73%3384.37%-0.69%-1521.74%95.94%-180.74%3319.19%96.38%74.17%-129.83%-535.93%-113.33%1400%-50%100%
Net Income-31.45M-15.7M-9.96M-21.72M-28.95M-26.98M-23.79M-29.14M-22.4M-10.45M-14.41M-13.36M-17.71M-14.56M-9.42M-9.22M-1.32M15.05M-1.04M-748.98K-367.18K-530.61K-123.15K-1.28M-2.6M1.34M-2.86M-1.7M-400K-2.3M-600K
Depreciation & Amortization8.56M8.19M7.84M5.55M4.85M4.74M3.46M2.88M851K566.6K436.49K248.97K198.89K138.33K314.83K340.68K19.77K23.01K23.12K22.27K25.46K20.04K212.28K523.27K625.14K521.28K908.02K900K800K1M1.1M
Stock-Based Compensation34.05M30.11M15.91M14.42M15.59M10.92M8.47M10.3M7.61M3.61M1.39M1.32M956.45K671.89K495.08K250.04K245.26K0455.08K000000000000
Deferred Taxes000003.37M2.21M04.38M223.32K830.07K125.37K936.67K68.04K447.48K10.47M-586K48K00000000157K000-100K
Other Non-Cash Items18.46M2.83M797K415K2M831K232K1.53M81K246.56K2.05M589.56K5.28M3.96M1.3M-9.21M0-130K0332.93K31.65K86.78K2.04M52.38K27.11K-4.39M730K-100K100K2.3M0
Working Capital Changes-14.05M-24.62M-10.04M-4.39M-9.56M-6.28M-209K-5.45M-8.38M-3.44M-1.5M-1.98M-114.13K-728.44K-1.8M294.19K-792.39K454.6K92.34K-73.17K281.28K-285.83K-1.25M678.82K1.2M-400.38K-207.61K700K1M-900K-200K
Change in Receivables-2.11M-2.46M392K-2.69M-4.64M-499K-635K-2.14M-5.11M-3.24M-3.35M-2.04M-1.01M-902.23K-252.44K-368.95K000000000000000
Change in Inventory-10.57M-9.19M-10.16M-6.05M-3.66M-7.48M-910K-3.77M-6.01M-1.86M-1.52M-720.34K184.82K-247.33K-1.39M142.25K0000000-82.68K516.75K-177.65K-336.16K-300K900K-600K-300K
Change in Payables1.35M-7.16M125K6.51M660K-270K4.96M2.92M3.71M1.93M3.44M1.12M498.29K430.58K-105.35K0-22.35K58.5K12.75K000000000000
Cash from Investing-22.62M-5.32M-10.3M19.25M-3.2M-23.65M-16.96M27.27M-98.19M-1.29M-1.19M-555.52K-594.05K-243.97K-127.28K7.11M-2M-8.68K-29.91K00-60K862.68K773.09K-102.07K6.16M-563K-500K100K-300K-600K
Capital Expenditures-6.28M-3.75M0-13.87M-21.25M-28.4M-22.6M-4.66M-6.6M-1.29M-1.19M-555.52K-594.05K-243.97K-127.28K-89.47K-40.7K-8.68K-29.91K000-74.55K-22K-21.07K-371.91K-424.45K-400K-400K-200K-400K
CapEx % of Revenue2.64%1.66%2.41%8.72%15.34%22.3%20.12%4.37%7.87%2.14%2.89%2.03%3.53%2.23%1.65%1.84%44.59%0.03%41.14%---7%0.3%0.31%2.33%2.91%3.25%3.1%1.63%3.05%
Acquisitions00003.2M-589K692K0321K0000007.2M000000000000000
Investments-------------------------------
Other Investing-1.62M-1.85M-10.3M-1.05M-3.2M1.54M-692K-562K-321K-187K-226K-146.74K-52K-65.19K-78.83K000000-60K937.23K795.1K-81K6.53M-138.55K-100K-100K-100K-200K
Cash from Financing67.62M10.5M2.29M1.95M1.79M20.45M40.47M4.03M109.84M17.02M16.5M31.3M-808.85K16.85M14.51M6.36M-4.26M0018.09K0-159.12K13.96K-933.54K103.48K34.73K913.01K-500K-100K0300K
Debt Issued (Net)-69.79M-32K-10K-10K-12K14.98M34.99M29K-22.51M-21K-3.25M0-1.75M015.8M5.77M00000-2.52K-12.57K-936.73K101.2K07K859.42K000
Equity Issued (Net)143.23M10.53M2.3M1.96M1.81M5.47M3.5M0015.89M19.75M30.97M1.63M16.78M01M39K0018.09K06.45K8.75K3.19K2.27K028K53.59K-500K-200K0
Dividends Paid0000000000000000-4.3M0000-246.82K000000000
Share Repurchases0000000000000000000000000000-500K-200K-200K
Other Financing-5.82M000001.99M4M132.35M1.15M0332.66K-684.6K73.33K-1.29M-408.29K0000083.78K17.78K0034.73K878.01K00100K0
Net Change in Cash60.56M5.99M-3.47M15.49M-17.47M-16.6M13.88M11.43M-6.21M6.49M4.1M17.69M-11.85M6.16M5.72M6.39M-8.69M15.43M-500.08K-448.86K-28.79K-928.74K1.76M-187.74K-753.62K3.28M-921.85K-1.2M1.5M-200K-100K
Free Cash Flow8.93M-2.93M11K-20.63M-37.32M-41.8M-32.22M-25.1M-24.46M-10.53M-12.39M-13.61M-11.05M-10.69M-8.79M-7.17M-2.47M15.43M-500.08K-466.95K-28.79K-709.62K804.29K-49.3K-776.09K-3.3M-1.7M-600K1.1M-100K-200K
FCF Margin %3.75%-1.3%0.01%-12.98%-26.93%-32.82%-28.69%-23.52%-29.15%-17.43%-30.15%-49.79%-65.68%-97.64%-114.27%-147.83%-2706.56%61.95%-687.76%-464.94%-22.73%-160.06%75.52%-0.68%-11.33%-20.69%-11.62%-4.88%8.53%-0.81%-1.53%
FCF Growth %4781.42%-26763.64%100.05%44.71%10.73%-29.74%-28.39%-2.59%-132.34%15.04%8.92%-23.2%-3.33%-21.61%-22.6%-190.19%-116.01%3186.18%-7.09%-1521.74%95.94%-188.23%1731.38%93.65%76.45%-94.25%-182.72%-154.55%1200%50%85.71%
FCF per Share0.17-0.060.00-0.48-0.89-1.01-0.81-0.64-0.66-0.32-0.40-0.52-0.62-0.79-0.79-1.94-0.573.58-0.12-0.11-0.01-0.170.20-0.01-0.20-0.84-0.44-0.150.27-0.03-0.05
FCF Conversion (FCF/Net Income)-0.28x-0.05x-0.46x0.26x0.55x0.50x0.40x0.68x0.80x0.88x0.78x0.98x0.59x0.72x0.92x0.77x1.85x1.03x0.45x0.62x0.08x1.34x0.38x0.02x0.29x-2.18x0.44x0.12x-3.75x-0.04x-0.33x
Interest Paid1.53M00000034K00000000000000000000000
Taxes Paid0000000000000000000000000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityNegative
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

BLA regulatory approval timeline

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Masked by Accruals

According to reported financial data, the relationship between net income and operating cash flow remains highly volatile, with OCF/NI ratios swinging from -0.08 in 2026Q1 to 19.41 in 2024Q4, suggesting that GAAP earnings are currently poor indicators of the company's actual cash-generating capacity.

The significant divergence between net income and operating cash flow appears driven by heavy non-cash charges and working capital fluctuations. Investors should monitor whether this volatility persists as the company attempts to stabilize its manufacturing output at the new Alachua facility.

Inconsistent Free Cash Flow Generation

As reported in quarterly filings, AXGN's free cash flow trajectory is erratic, oscillating between a peak margin of 16.0% in 2024Q4 and a low of -32.9% in 2024Q1, indicating that the business has yet to achieve a self-sustaining cash flow profile.

The inability to maintain positive FCF suggests that the company's growth strategy remains heavily reliant on external capital or cash reserves. This pattern warrants further investigation into whether the current cost structure can support long-term profitability without continued cash burn.

Capital Intensity Reflects Facility Scaling

Based on recent SEC filings, AXGN's capital expenditure as a percentage of revenue has fluctuated between 0.5% and 4.5%, reflecting the lumpy nature of investments required to transition to the new centralized processing facility in Alachua, Florida.

While current capex levels appear manageable, the investment cycle is clearly tied to operational scaling rather than routine maintenance. Analysts should interpret these figures as a commitment to long-term capacity, though the immediate impact on cash flow remains a drag.

Working Capital Volatility Hinders Liquidity

Data from financial statements reveals significant working capital swings, including a $14.7M outflow in 2025Q1, which suggests that inventory management and collection cycles are currently creating substantial, unpredictable pressure on the company's quarterly operating cash flow.

These fluctuations may indicate challenges in aligning tissue procurement and processing with actual surgical demand. Investors should monitor whether these working capital dynamics normalize as the company gains experience with its new manufacturing footprint.

SBC Obscures True Cash Burn

As reported in recent filings, stock-based compensation reached $16.6M in 2025Q4, a figure that significantly exceeds net income and suggests that the company's reported cash flow metrics may be artificially supported by non-cash equity-based incentives.

The reliance on SBC as a primary tool for talent retention effectively shifts the cost of growth from cash to dilution. This practice appears to mask the true economic cost of operations, making it difficult to assess the company's underlying path to cash-flow neutrality.

AXGN — Frequently Asked Questions

Quick answers to the most common questions about buying AXGN stock.

How much cash does AxoGen, Inc. (AXGN) generate from operations?

AxoGen, Inc. (AXGN) generated $0.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is AxoGen, Inc.'s free cash flow?

AxoGen, Inc. (AXGN) reported negative free cash flow of $2.9M in 2025, indicating capital requirements exceeded cash from operations.

What is AxoGen, Inc.'s capital expenditure (CapEx)?

AxoGen, Inc. (AXGN) spent $3.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.